INDEMNIFICATION AGREEMENTIndemnification Agreement • April 27th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [DATE], 2015 between Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (the “Company”), and [NAME] (“Indemnitee”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • April 27th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of October 15, 2015 between Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (the “Company”), and [NAME] (“Indemnitee”).
Confidential Treatment Requested by Kiniksa Pharmaceuticals, Ltd. LICENSE AGREEMENT between MEDIMMUNE, LIMITED and KINIKSA PHARMACEUTICALS, LTD.License Agreement • April 27th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations
This License Agreement (the “Agreement”) is made and entered into effective as of December 21, 2017 (the “Effective Date”) by and between MedImmune, Limited, a limited liability company duly authorized and existing under the laws of England and Wales (“MedImmune”) and Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (“Licensee”). MedImmune and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ASSET PURCHASE AGREEMENT between KINIKSA PHARMACEUTICALS, LTD. and BIOGEN MA INC. dated as of September 7, 2016 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been...Asset Purchase Agreement • April 27th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
This Asset Purchase Agreement (this “Agreement”) is made and entered into as of September 7, 2016 (the “Effective Date”), between Biogen MA Inc., a Massachusetts corporation (“Biogen”), and Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (“Kiniksa”). Kiniksa and Biogen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CLINICAL SUPPLY AGREEMENTClinical Supply Agreement • April 27th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
THIS CLINICAL SUPPLY AGREEMENT (“Agreement”) effective as of September 27, 2017 (“Effective Date”), is by and between Regeneron Pharmaceuticals, Inc. (“Regeneron”), and Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (“KINIKSA”). Regeneron and KINIKSA are sometimes hereinafter referred to as a “Party” and collectively as the “Parties”.
Confidential Treatment Requested by Kiniksa Pharmaceuticals, Ltd. LICENSE AGREEMENT By and Between REGENERON PHARMACEUTICALS, INC. and KINIKSA PHARMACEUTICALS, LTD. Dated as of September 25, 2017License Agreement • April 27th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
